What is the total value of the Clario acquisition?

The base cash purchase price is $8.875 billion at closing. Thermo Fisher also agreed to pay $125 million in January 2027 as deferred consideration and up to $400 million in earn-out payments based on Clario's performance in 2026 and 2027. The maximum total is therefore about $9.4 billion, before any other adjustments.

How will Thermo Fisher pay for the deal, and what does that mean for its balance sheet?

The company intends to use proceeds from debt financing and cash on hand. Because the filing does not specify the size of the new debt, investors should expect higher leverage and interest costs, and should watch for disclosure on the financing mix and any resulting changes to credit metrics or buyback plans.

Will the deal help or hurt earnings per share?

Management says the acquisition is immediately accretive to adjusted EPS and will add $0.45 of adjusted EPS in the first year after close. These are non-GAAP figures that exclude certain items, and GAAP results may differ because of amortization of acquired intangibles, transaction costs, and financing costs, which the filing does not quantify.

When is the transaction expected to close, and what could prevent it?

Closing is expected by the middle of 2026, subject to customary closing conditions and regulatory approvals. The forward-looking statements also note risks such as approvals not being obtained on time or at all, or being granted with conditions, disruption to Clario's business, difficulty retaining key employees, and legal proceedings related to the deal. Investors should check later filings for the actual closing status, since the current date is past the expected closing window.

Is the deal strategically important for Thermo Fisher?

Management positions Clario as a strong strategic fit that expands Thermo Fisher's digital and data capabilities, strengthens its AI use in clinical research, and adds high-growth capabilities for pharma and biotech customers. Clario will sit in the Laboratory Products and Biopharma Services segment. The expected payoff is about $175 million of adjusted operating income from synergies by year five, mostly from revenue synergies.

TMO 8-K SEC Disclosure — Oct 29, 2025

01—Abstract

Summary

Summary of the 8-K filed October 29, 2025. Cited figures are marked; the original filing is the authoritative source.

On October 29, 2025, Thermo Fisher Scientific (TMO) disclosed a definitive agreement to acquire Clario Holdings, Inc., a provider of endpoint data solutions for clinical trials, from a shareholder group led by Astorg and Nordic Capital, Novo Holding, and Cinven.

The consideration is $8.875 billion^a in cash at closing, plus a $125 million deferred payment due in January 2027 and up to $400 million in earn-out payments tied to Clario's performance in 2026 and 2027. Clario is expected to generate about $1.25 billion of revenue in 2025, which implies roughly 7.1x revenue on the closing cash price before deferred and contingent payments. Management says the deal is immediately accretive to adjusted EPS after closing and adds $0.45 of adjusted EPS in the first year.

They also expect a double-digit internal rate of return, high-single-digit growth under Thermo Fisher ownership, and about $175 million^b of adjusted operating income from synergies by year five, mainly from revenue synergies. Clario will join the Laboratory Products and Biopharma Services segment. The company plans to fund the deal with debt financing and cash on hand, and closing is expected by the middle of 2026, subject to customary conditions and regulatory approvals.

For investors, the key questions are the scale of new debt, whether the accretion and synergy targets are achieved, and execution risk around integration and regulatory review. The filing's forward-looking statements flag these risks, including possible failure to obtain approvals, business disruption at Clario, employee retention, and shortfalls in expected synergies. The 8-K does not disclose the purchase price allocation, the amount of new debt, or Clario's profitability, so those details will matter for assessing the deal's returns.

02—Key points

Key Highlights

Acquisition of Clario Holdings for $8.875 billion in cash at closing, plus a $125 million deferred payment due January 2027 and up to $400 million in earn-outs tied to 2026–2027 performance.
Clario is a leading provider of clinical trial endpoint data (eCOA, medical imaging, cardiac, respiratory, wearables), with its platform reportedly supporting about 70% of FDA drug approvals over the past decade.
Clario expected to generate approximately $1.25 billion of 2025 revenue and has about 4,000 employees; the headline cash price implies roughly 7.1x 2025 revenue.
Management expects the deal to be immediately accretive to adjusted EPS after close, adding $0.45 of adjusted EPS in the first year, and to be immediately accretive to adjusted operating margin.
Expected synergies of approximately $175 million of adjusted operating income by year five, primarily from revenue synergies; management cites a double-digit internal rate of return and high-single-digit growth under Thermo Fisher ownership.
Funding will come from debt financing and cash on hand, which raises leverage and interest expense considerations for investors.
Expected closing by the middle of 2026, subject to customary conditions and regulatory approvals; Clario will join the Laboratory Products and Biopharma Services segment.

03—Questions

Frequently Asked Questions

What is the total value of the Clario acquisition?
The base cash purchase price is $8.875 billion at closing. Thermo Fisher also agreed to pay $125 million in January 2027 as deferred consideration and up to $400 million in earn-out payments based on Clario's performance in 2026 and 2027. The maximum total is therefore about $9.4 billion, before any other adjustments.
How will Thermo Fisher pay for the deal, and what does that mean for its balance sheet?
The company intends to use proceeds from debt financing and cash on hand. Because the filing does not specify the size of the new debt, investors should expect higher leverage and interest costs, and should watch for disclosure on the financing mix and any resulting changes to credit metrics or buyback plans.
Will the deal help or hurt earnings per share?
Management says the acquisition is immediately accretive to adjusted EPS and will add $0.45 of adjusted EPS in the first year after close. These are non-GAAP figures that exclude certain items, and GAAP results may differ because of amortization of acquired intangibles, transaction costs, and financing costs, which the filing does not quantify.
When is the transaction expected to close, and what could prevent it?
Closing is expected by the middle of 2026, subject to customary closing conditions and regulatory approvals. The forward-looking statements also note risks such as approvals not being obtained on time or at all, or being granted with conditions, disruption to Clario's business, difficulty retaining key employees, and legal proceedings related to the deal. Investors should check later filings for the actual closing status, since the current date is past the expected closing window.
Is the deal strategically important for Thermo Fisher?
Management positions Clario as a strong strategic fit that expands Thermo Fisher's digital and data capabilities, strengthens its AI use in clinical research, and adds high-growth capabilities for pharma and biotech customers. Clario will sit in the Laboratory Products and Biopharma Services segment. The expected payoff is about $175 million of adjusted operating income from synergies by year five, mostly from revenue synergies.

04—Continue

← View all 8-K filings